Stockreport

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics, Inc.  (CADL) 
PDF Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical [Read more]